home.social

#solidtumors — Public Fediverse posts

Live and recent posts from across the Fediverse tagged #solidtumors, aggregated by home.social.

fetched live
  1. Clonal hematopoiesis of indeterminate potential: a multisystem hub bridging hematopoietic dysfunction with non-hematopoietic diseases | Military Medical Research

    Blokzijl F, de Ligt J, Jager M, Sasselli V, Roerink S, Sasaki N, et al. Tissue-specific mutation accumulation…
    #NewsBeep #News #Health #atherosclerosis #AU #Australia #chronicinflammation #Clonalhematopoiesisofindeterminatepotential(CHIP) #Emergencymedicine #infection #solidtumors
    newsbeep.com/au/212505/

  2. Gilead bets on Xilio cancer drug as biotech restructures—Sanders blasts Novo Nordisk for ‘outrageous’ price of Ozempic, Wegovy—Boundless Bio breaks IPO lull with $100M fundraise--bit.ly/w28kSd #gileadsciences #solidtumors #berniesanders #drugpricing #novonordisk #ozempic #wegovy #ipos #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

  3. Gilead bets on Xilio cancer drug as biotech restructures—Sanders blasts Novo Nordisk for ‘outrageous’ price of Ozempic, Wegovy—Boundless Bio breaks IPO lull with $100M fundraise--bit.ly/w28kSd #gileadsciences #solidtumors #berniesanders #drugpricing #novonordisk #ozempic #wegovy #ipos #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

  4. Gilead bets on Xilio cancer drug as biotech restructures—Sanders blasts Novo Nordisk for ‘outrageous’ price of Ozempic, Wegovy—Boundless Bio breaks IPO lull with $100M fundraise--bit.ly/w28kSd #gileadsciences #solidtumors #berniesanders #drugpricing #novonordisk #ozempic #wegovy #ipos #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

  5. AbbVie CEO Richard Gonzalez to step down, Robert Michael to succeed him —Medtronic lifts annual profit forecast, exits ventilator business—FDA approves Iovance's Amtagvi as first T-cell therapy for a solid tumor--bit.ly/w28kSd #abbvie #ceos #medtech #medtronic #earnings #ventilators #solidtumors #fda #tcelltherapy #iovance #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

  6. AbbVie CEO Richard Gonzalez to step down, Robert Michael to succeed him —Medtronic lifts annual profit forecast, exits ventilator business—FDA approves Iovance's Amtagvi as first T-cell therapy for a solid tumor--bit.ly/w28kSd #abbvie #ceos #medtech #medtronic #earnings #ventilators #solidtumors #fda #tcelltherapy #iovance #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

  7. Roche drops oral eye disease drug after completing phase 2, pulls back from solid tumor bispecific-- Lilly links up European ADC network, snagging Elahere rival in latest biotech buy --Pfizer to pay $2M settlement for alleged gender wage discrimination -- See more on our front page news bit.ly/w28kSd #roche #solidtumors #elililly #mergersandacquisitions #pfizer #genderdiscrimination #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

  8. Roche's divarasib scores phase 1 win in KRAS-mutated solid tumors -- AbbVie removes two early-stage cancer assets from pipeline -- Vivek Ramaswamy’s brashness made waves in the Republican debate -- See more on our front page news bit.ly/w28kSd #roche #clinicaltrials #solidtumors #KRAS #cancer #abbvie #vivekramaswamy #presidentialelection2024 #republicandebate #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

  9. Two important papers on #talazoparib and #avelumab in #solidtumors. Take home messsage: BRCA is associated with most responses and no clear advantage of combo over monotherapy with a caveat of being careful about cross-trial comparisons

  10. Two important papers on #talazoparib and #avelumab in #solidtumors. Take home messsage: BRCA is associated with most responses and no clear advantage of combo over monotherapy with a caveat of being careful about cross-trial comparisons

  11. Two important papers on #talazoparib and #avelumab in #solidtumors. Take home messsage: BRCA is associated with most responses and no clear advantage of combo over monotherapy with a caveat of being careful about cross-trial comparisons

  12. Two important papers on #talazoparib and #avelumab in #solidtumors. Take home messsage: BRCA is associated with most responses and no clear advantage of combo over monotherapy with a caveat of being careful about cross-trial comparisons

  13. Two important papers on #talazoparib and #avelumab in #solidtumors. Take home messsage: BRCA is associated with most responses and no clear advantage of combo over monotherapy with a caveat of being careful about cross-trial comparisons